RxDoctor Payments Data

Ozgur Oztas, MD

Neurology · Mobile, ALNPI 1174572747

Payments from drug & device makers

$19,004in general payments, 2019–2025

Across 1,182 payments — averaging $16.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novartis$2K
  • Biogen$1K
  • UCB, Inc.$984
  • Amgen$941
  • Acadia Pharmaceuticals Inc$876
  • plus $10K from 54 others

What the payments were for

  • Speaking & faculty fees$660%
  • Food & beverage$18,89799%
  • Education$420%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)231$2,786
Novartis140$1,957
Biogen86$1,099
UCB, Inc.54$984
Amgen(2 entities)53$941
Acadia Pharmaceuticals Inc48$876
SK Life Science, Inc.38$846
Sanofi37$778
AstraZeneca(2 entities)32$688
Eisai Inc.39$668
EMD Serono, Inc.32$616
Lundbeck LLC31$547
Teva Pharmaceuticals USA, Inc.27$509
Neurocrine Biosciences, Inc.28$456
Bristol Myers Squibb26$428
Pfizer21$364
Kyowa Kirin, Inc.18$347
Adamas Pharmaceuticals, Inc.12$267
MDD US Operations, LLC14$247
Biohaven Pharmaceutical Holding Company Ltd.15$203
Supernus Pharmaceuticals, Inc.13$195
Acorda Therapeutics, Inc11$195
Argenx US, Inc.6$194
Mallinckrodt Hospital Products Inc.11$194
Impel Pharmaceuticals Inc.14$190
Tanabe Pharma America, Inc.10$182
Lilly USA, LLC9$145
Axsome Therapeutics, Inc.10$139
Ipsen Biopharmaceuticals, Inc9$133
Genentech USA, Inc.8$132
Sunovion Pharmaceuticals Inc.8$124
Johnson & Johnson(2 entities)7$123
Otsuka America Pharmaceutical, Inc.6$121
CSL Behring3$96
Arbor Pharmaceuticals, Inc.7$96
Grifols USA, LLC4$87
ANI Pharmaceuticals, Inc.4$80
Greenwich Biosciences, Inc.4$76
Medtronic5$75
Amneal Pharmaceuticals LLC6$73
Upsher-smith Laboratories LLC5$72
Alnylam Pharmaceuticals Inc.3$72
Mallinckrodt Enterprises LLC5$70
Catalyst Pharmaceuticals, Inc.4$64
Neurelis, Inc.3$52
Merz Pharmaceuticals, LLC2$37
Takeda Pharmaceuticals U.S.A., Inc.2$37
Avion Pharmaceuticals2$35
Harmony Biosciences LLC2$33
Sumitomo Pharma America, Inc.2$32
Abbott2$32
Zyla Life Sciences, Inc.2$31
Life Molecular Imaging Ltd1$25
Scilex Pharmaceuticals Inc.1$22
Jazz Pharmaceuticals Inc.1$18
Assertio Therapeutics, Inc.1$16
Endo Pharmaceuticals Inc.1$15
Merz North America, Inc.1$15
Boston Scientific1$14
Averitas Pharma Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,004 in reported general payments places this provider in the 70th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama

Medicare billing

Part B allowed, 2024
$188,323
Medicare patients
634
Services billed
1,783

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NamzaricMemantine Hcl/Donepezil Hcl33$37,520
QuliptaAtogepant33$34,615
Nurtec OdtRimegepant Sulfate19$28,503
UbrelvyUbrogepant18$25,685
Emgality PenGalcanezumab-Gnlm33$22,540
EliquisApixaban25$19,629
FycompaPerampanel14$17,748
Memantine Hcl480$13,310
Donepezil Hcl646$8,738
Carbidopa-LevodopaCarbidopa/Levodopa173$7,232
RivastigmineRivastigmine Tartrate117$6,560
Primidone191$5,946
Gabapentin306$5,693
Amitriptyline Hcl277$4,358
Levetiracetam144$3,614

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieNamzaric, Qulipta, Ubrelvy$2,786$97,81984 claims
PfizerNurtec Odt, Eliquis$364$48,13344 claims
Eisai Inc.Fycompa$668$17,74814 claims
Upsher-smith Laboratories LLCTopiramate$72$1,337129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 255 neurology providers in Alabama.

Other neurology in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →